Quantexa Launches New Asia Pacific Headquarters in Singapore to Capture Next Wave of Growth
- Quantexa’s growing presence in Singapore represents significant investment in delivering AI-enabled Decision Intelligence (DI) solutions to Enterprises and Government Agencies across Asia Pacific
- Quantexa has seen double-digit growth and tripled employee base in Asia Pacific region since Series D announcement in 2022
- The new location in Singapore reinforces Quantexa’s global network and brings the company closer to its clients and partners in the region
SINGAPORE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Quantexa, the global leader in Decision Intelligence (DI) solutions for the public and private sectors, today announced the opening of its new Asia Pacific Headquarters based in Tower 1 of Marina Bay Financial Centre (MBFC) in Singapore. The opening is part of a broader regional expansion plan and follows the July 2023 launch of Quantexa’s Japan operations in Tokyo and long-standing presence in Melbourne, Sydney and Malaysia. Further expansion into Hong Kong is expected in 2024.
The organization’s decision to set up its regional headquarters in Singapore was solidified by the country’s commitment to attracting investment, talent, and technology. Establishing Quantexa’s new office locally complements the government’s Smart Nation initiative which outlines its plan to invest up to SGD500 million in Artificial Intelligence (AI) research and development.
Economic forecasts for Southeast Asia predict that it will remain one of the fastest growing regions for years to come. Additionally, over the past 12 months, Quantexa has seen significant demand in the region as local banks and government agencies put an increased emphasis on detecting and preventing financial crime as the number of large-scale money laundering operations in region have risen, costing victims abroad billions of dollars. Recently, Singapore authorities have taken measures to ensure that financial institutions scrutinise monetary flows with city state managed assets valued at USD4 trillion.
Quantexa’s regional headquarters will provide sales, marketing, product management, and professional services capabilities to support customer implementations of its Decision Intelligence Platform in the banking, insurance and telecommunications industries, as well as the public sector. The opening comes after Quantexa recently completed its Series E Funding Round led by GIC Singapore, valuing the company north of $1.8 billion, and announcing a $155 million investment to fuel global artificial intelligence advancements.
Today, Quantexa will host an event to showcase local technology innovation and partnerships at The National Museum of Singapore. Quantexa CEO Vishal Marria will be joined by esteemed industry leaders from GIC, Singapore’s Digital and Intelligence Service (DIS), and Standard Chartered Bank for a panel discussion on “Charting New Pathways for AI Innovation.”
Vishal Marria, CEO and Founder, Quantexa, said:“Quantexa has seen 90% revenue growth and we have nearly tripled our team size in the Asia Pacific region since our Series D announcement. With today’s announcement of our new regional headquarters in Singapore, we continue to accelerate our growth plans and get closer to our clients and partners as we serve the region.”
Choo Yong Cheen, Chief Investment Officer of Private Equity, GIC, said: “We are pleased to see Quantexa establish their new regional headquarters in Singapore as part of their expansion efforts in Asia. As Quantexa continues to benefit from increasing regulatory emphasis on compliance and demand for AI capabilities in data management, we remain confident in the company's growth potential.”
Jinghua Guo, Chief Digitization Officer, The Digital and Intelligence Service, added: “The Digital and Intelligence Service views AI as a mission-critical capability for the Singapore Armed Forces to safeguard the sovereignty and security of Singapore. We have always worked closely with other technology partners in government to build cutting-edge AI capabilities for defence. But beyond this, we need to harness the rapid innovations from commercial companies as part of our AI portfolio to address our operational needs more effectively. Therefore, we are interested to further explore how cutting-edge solutions from technology leaders like Quantexa can help us succeed in our mission.”
Sean Coppinger, CIO, Standard Chartered Bank, said: “We are thrilledthat Quantexa is expanding itspresence here. Since 2018, we have worked closely with Quantexa to use AI-enabled data matching capabilities to get a complete view of our customers and their transaction networks. This has helped us raise the bar on how the industry detects fraud and fights financial crime.”
The Singapore Headquarters joins a growing portfolio of Quantexa hubs including London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.
Quantexa’s Asia Pacific team is expanding and is actively recruiting several open positions. To find out more about current vacancies, visit this page.
Note to Editors:
For more information on Quantexa, please visit the website here.
C: Alina Boey, Senior Consultant, Milk & Honey PR
T: +65 96565580
Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.
The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 675 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.
GIC is a leading global investment firm established in 1981 to secure Singapore’s financial future. As the manager of Singapore’s foreign reserves, GIC takes a long-term, disciplined approach to investing and is uniquely positioned across a wide range of asset classes and active strategies globally. These include equities, fixed income, real estate, private equity, venture capital, and infrastructure. Its long- term approach, multi-asset capabilities, and global connectivity enable it to be an investor of choice. GIC seeks to add meaningful value to its investments. Headquartered in Singapore, GIC has a global talent force of over 2,100 people in 11 key financial cities and has investments in over 40 countries. For more information, please visit www.gic.com.sg or follow on LinkedIn.
 Source: Nikkei Asia article - Singapore stands out as a global tech hub amid U.S.-China tensions
 Source: South China Morning Post article - Singapore readies roll out of anti-money-laundering platform to prevent a 1MDB repeatTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant7.12.2023 07:35:00 CET | Press release
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd aloneFirst global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in transplant-ineligible patients, reinforcing the potential for Sarclisa as a best-in-class medicineStudy results will be submitted for presentation at an upcoming medical meeting and form the basis of a future regulatory submission PARIS, December 7, 2023. The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free surviva
Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release
Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: IR@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage7.12.2023 07:00:00 CET | Press release
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held v